Top dermatology news: IBD risk in hidradenitis suppurativa, missed nonmelanoma subtypes

Hemali Gunt

Researchers in JAMA Dermatology warned clinicians about an increased risk for inflammatory bowel disease among those with hidradenitis suppurativa, which gained the most pageviews on Healio Dermatology last week.

In another top story, nonmelanoma skin cancer tumors that have been upgraded in subtype require significantly more stages and specimens for tumor clearance, according to researchers studying features of aggressive cancers that were not apparent on the initial biopsy.

Patients with hidradenitis suppurativa at greater risk for IBD

“There is an urgent need for the generation of new knowledge to advance the field and improve care of patients with HS,” Haley B. Naik, MD, MHSc, at the department of dermatology at the University of California, San Francisco, and Michelle A. Lowes, MBBS, PhD, at Rockefeller University, New York, wrote in an accompanying editorial. Read more.

Nonmelanoma skin cancers may be more aggressive than initial biopsy suggests

“Clinicians should consider the importance of sampling an adequate amount of tissue to enable accurate diagnosis when one of these aggressive subtypes, which are associated with increased risk for recurrence, are suspected,” Rachel L. Kyllo, MD, from the division of dermatology at Washington University School of Medicine, St. Louis, and colleagues wrote. Read more.

Nature-based skin care may improve barrier function, decrease sensitivity

“This work shows the important role that nature-based skin care products may play in improving barrier and decreasing skin sensitivity in highly polluted environments,” Hemali Gunt, PhD, head of clinical affairs at Burt’s Bees, said in an interview. Read more.